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family with three affected members
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Abstract 
Multiple osteochondromas (also called hereditary multiple exostoses) is an autosomal dominant disorder character-
ized by multiple cartilaginous tumors, which are caused by mutations in the genes for exostosin-1 (EXT1) and exos-
tosin-2 (EXT2). The goal of this study was to elucidate the genetic alterations in a family with three affected members. 
Isolation of RNA from the patients’ blood followed by reverse transcription and PCR amplification of selected frag-
ments showed that the three patients lack a specific region of 90 bp from their EXT1 mRNA. This region corresponds 
to the sequence of exon 8 from the EXT1 gene. No splice site mutation was found around exon 8. However, long-
range PCR amplification of the region from intron 7 to intron 8 indicated that the three patients contain a deletion 
of 4318 bp, which includes exon 8 and part of the flanking introns. There is evidence that the deletion was caused 
by non-homologous end joining because the breakpoints are not located within a repetitive element, but contain 
multiple copies of the deletion hotspot sequence TGRRKM. Exon 8 encodes part of the active site of the EXT1 enzyme, 
including the DXD signature of all UDP-sugar glycosyltransferases. It is conceivable that the mutant protein exerts a 
dominant negative effect on the activity of the EXT glycosyltransferase since it might interact with normal copies of 
the enzyme to form an inactive hetero-oligomeric complex. We suggest that sequencing of RNA might be superior to 
exome sequencing to detect short deletions of a single exon.
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Background
Multiple osteochondromas (MO), also called heredi-
tary multiple exostoses (HME), is a genetic, autosomal 
dominant disorder characterized by multiple benign 
cartilaginous tumors. These tumors (or exostoses) form 
next to the growth plate of long bones, ribs and pel-
vis and protrude into the adjacent perichondrium and 
neighboring tissue (Huegel et  al. 2013). Patients with 
MO are frequently of short stature and show short-
ened forearms, changes in the angle of fingers and ankle 
and unequal length of limbs. Most of the patients have 
to undergo repetitive surgery to remove some of the 
exostoses because they cause pain or functional impair-
ment (Pedrini et al. 2011). The most serious complication 
of MO is a malignant transformation into a secondary 
chondrosarcoma, which occurs in 1–5 % of the patients.
MO is caused by heterozygous inactivating muta-
tions of the genes for exostosin-1 (EXT1) or exostosin-2 
(EXT2). The majority of these mutations are nonsense, 
frame shift and splice-site mutations, but there are also 
missense mutations and deletions (Jennes et  al. 2009; 
Pedrini et  al. 2011). About 65  % of the MO mutations 
occur in EXT1 and 25 % in EXT2. The residual 10 % of 
the patients do not display any overt mutations in EXT1 
or EXT2. Recent results suggest, however, that some of 
these cases might be explained by somatic, mosaic muta-
tions in the EXT genes (loss of heterozygosity) and/or by 
mutations in some of the large introns (Szuhai et al. 2011; 
Waaijer et al. 2013).
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EXT1 and EXT2 code for glycosyltransferases in the 
Golgi apparatus that are involved in the formation of 
heparan sulfate chains for proteoglycans (Esko and Sell-
eck 2002; Nadanaka and Kitagawa 2008). Both enzymes 
are typical type II transmembrane proteins with the 
C-terminal part of the protein outside of the membrane. 
The growth plate of long bones is known to contain large 
amounts of heparan sulfate proteoglycans, mainly synde-
can, glypican and perlecan (Farach-Carson et  al. 2005). 
EXT1 and EXT2 belong to a small family of related pro-
teins, which also includes the three exostosin-like pro-
teins EXTL1, EXTL2 and EXTL3. With the exception 
of EXTL2, all EXT proteins contain a transmembrane 
domain at the N-terminal end, an Exostosin interaction 
domain in the center and a catalytic domain at the C-ter-
minal end (Additional file 1: Fig. S1). EXTL2 in contrast 
contains only the transmembrane domain and the cata-
lytic domain. EXT1 and EXT2 form a hetero-oligomeric 
complex (Kobayashi et al. 2000; McCormick et al. 2000; 
Senay et al. 2000) that adds repeating units of glucuronic 
acid (GlcA) and N-acetyl-glucosamine (GlcNAc) to the 
nascent chain of heparan sulfate. EXTL1, EXTL2 and 
EXTL3 on the other hand, appear to be involved in the 
addition of the first carbohydrate residue to the linker 
tetrasachararide of the proteoglycan core protein (Nad-
anaka and Kitagawa 2008).
Loss-of-function mutations in one allele of the EXT 
genes cause a significant decrease of glycosyltransferase 
activity. Why the loss of a single copy of EXT1 or EXT2 
leads to a nearly complete loss of enzymatic activity 
is not yet clear (Hall et  al. 2002). It is possible that the 
mutated proteins interact with normal proteins to form 
an inactive hetero-oligomeric complex. Furthermore, 
studies with isolated chondrocytes from patients showed 
that cells with an EXT mutation have a significantly 
decreased survival rate (Hecht et al. 2005). At any rate, 
the decrease in glycosyltransferase activity leads to a 
general deficiency of heparan sulfate in the growth plate. 
This deficiency causes an increase in the distribution 
range of signaling proteins, including Ihh, BMP, FGF 
and Wnt. Diffusion of these signaling proteins is usually 
restricted by binding to heparan sulfate proteoglycans 
found on cell surfaces and in the extracellular matrix. 
Finally, the increased distribution range of the growth 
factors might initiate ectopic chondrogenesis and exos-
tosis formation.
In the present work we have studied a patient with MO 
from a family containing three affected members. The 
patient revealed a localized deletion of a single exon of 
EXT1. Deletions, especially deletions encompassing only 
a single exon have rarely been found with MO patients, 
probably because such deletions are more difficult to 
detect by conventional methods.
Results
Description of patients
The pedigree of the family of the index patient #13 is 
shown in Fig.  1. The index patient, who is currently 
34  years old, exhibited a length difference of his toes 
already at birth (Fig. 2a). At the age of 12, he was diag-
nosed to suffer from MO based on progressive exostoses 
at numerous locations, including toes, ankles, knees, 
hips, ribs, fingers, wrist, elbows and shoulders (Fig. 2b–
f). Repeated surgical interventions were required to cor-
rect functional impairment.
The currently 29-year-old younger brother (#14) of the 
index patient was diagnosed at the age of 12. Like his 
older brother, he had multiple exostoses, some of which 
required surgical resection. He shows shortened legs and 
forearms and has a mild walking impairment.
The 61-year-old mother (#8) of the index patient was 
diagnosed at age 10. Most of her limbs are shorter than 
normal. She underwent multiple surgical interventions 
before the age of 18 in order to remove exostoses. Due 
to a length difference of her legs she has severe walking 
impairment.
Based on these clinical findings it is likely that mother 
#8 harbors a de novo mutation, which was passed on to 
her sons #13 and #14. This mutation might have occurred 
early during development or alternatively, it was already 
present in the germline of one of the grandparents #1 or 
#2.
Identification of the mutation
Since the majority of the cases of MO can be explained 
by heterozygous mutations in EXT1 or EXT2 (Huegel 
et al. 2013; Jennes et al. 2009), we set out to determine the 
sequences of the open reading frames of these two genes 
from the index patient #13. Total RNA was extracted 
from freshly drawn blood and transcribed into cDNA. 
PCR amplification of overlapping fragments from these 
1 2
876543
41312111019
Fig. 1 Pedigree of the family of patient #13. Exostoses typical of MO 
were found only with mother #8 and her sons #13 and #14. Son #12, 
father #7, grandparents #1 and #2, aunt #3 and uncle #6 did not show 
any clinical signs of the disease
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cDNAs (see Additional file 1: Table S1) followed by DNA 
sequencing established the complete sequences of the 
EXT1 and EXT2 mRNAs. No mutation or polymorphism 
was found in EXT2. However, two relatively common 
polymorphisms were identified in EXT1, namely SNP 
rs11546829 A/G at position 1838 of the mRNA (global 
minor allele frequency MAF 0.173) and SNP rs7837891 
C/T at position 2534 (MAF 0.338). Neither of these pol-
ymorphisms will lead to any change in the amino acid 
sequence. In addition, a primer pair for region 2370-2723 
of EXT1 yielded two products that ran as two clearly sep-
arated bands on an agarose gel, a 354 bp fragment migrat-
ing with the band from a control cDNA (wildtype allele) 
and a novel 264 bp fragment (Fig. 3a). The two fragments 
were roughly obtained in a 1:1 ratio, suggesting that the 
264 bp fragment corresponded to the mutated allele. As 
expected, the novel 264  bp fragment was also obtained 
with RNA from the mother #8 and the younger brother 
#14, but not with RNA from the father #7 or the healthy 
brother #12. Finally, sequencing of the 264 bp fragment 
showed that the patients were lacking nucleotides 2406-
2495 of the EXT1 mRNA (NM_000127.2). The absence 
of these 90 bp could be verified on the coding as well as 
noncoding strand (Fig. 4a).
Nucleotides 2406-2495 of the mRNA correspond 
exactly to the region of the protein that is encoded by 
exon 8 of the EXT1 gene (Fig. 5). We therefore analyzed 
the splice sites of exon 8 using genomic DNA purified 
from the blood of the index patient. However, neither the 
donor splice site nor the acceptor splice site showed any 
alteration when compared to the published EXT1 gene 
sequence (NC_000008.11). It was therefore likely that our 
patient suffered from a localized deletion of exon 8.
To confirm this notion, we performed long-range PCR 
with genomic DNA. Utilizing two primers that annealed 
to intronic sequences adjacent to exon 7 and exon 9 
(Additional file  1: Table S1), we were able to amplify 
a fragment of 8  kb from an unrelated control and from 
father #7. However, with DNA from the index patient #13 
a b
c
d
f
e
Fig. 2 Phenotype of patient #13. A picture of the feet (a; age 34) 
shows unequal length of toes. An X-ray image of the right hand 
(b; age 19) shows an exostosis of the distal radius (arrow) and a 
shortened ulna. The X-ray of the pelvis (c; age 6) exhibits multiple 
exostoses on the pelvis and on the proximal femurs, which cause 
a locally irregular, tubercular aspect of the bone surface (arrows; 
compare the indicated regions with the contralateral side). The X-ray 
of the right knee (d; age 6) shows an osteochondroma on the head 
of the fibula (arrow). The X-ray of the left knee (e; age 6) demonstrates 
a prominent exostosis on the medial part of the femur (arrow). The 
X-ray of the lower legs (f; age 7) shows an osteochondroma at the 
distal end of the left fibula
▸
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we obtained two fragments, one of 8 kb (wildtype allele) 
and another one of 3.7 kb, which might include the dele-
tion (not shown). This observation was confirmed with a 
different primer set, which annealed closer to the center 
of the two introns. These primer pair amplified a frag-
ment of 5.6 kb from the unrelated control, from father #7 
and from the healthy brother #12, but two fragments of 
5.6 kb (wildtype allele) and 1.3 kb from the index patient 
#13 (Fig. 3b). DNA sequencing of the entire 1.3 kb frag-
ment on both strands (Fig.  4b) confirmed a deletion 
of 4318  bp. This deletion was situated between posi-
tion 117,814,822 and 117,810,504 of the EXT1 gene and 
encompassed exon 8 and part of the flanking introns. 
The region contained several repetitive elements, such 
as MIR, Alu, L2 and LTR (Fig. 6). The same deletion was 
also found with genomic DNA from the mother #8 and 
the younger brother #14 (not shown).
Mechanism of deletion
At least five mechanisms have been suggested to explain 
the occurrence of a genomic deletion, including (1) 
homologous recombination (HR), (2) non-homologous 
end-joining (NHEJ), (3) microhomology-mediated rep-
lication-dependent recombination (MMRDR), (4) long 
interspersed L1-mediated retrotransposition and (5) tel-
omere healing (Chen et  al. 2010). Since in our case no 
sequence homology was observed at the two deletion 
breakpoints and since these breakpoints did not occur 
within an L1 element, three of the above mentioned 
possibilities could be ruled out. Furthermore, the EXT1 
gene is not located at a telomere end but in chromo-
somal region 8p24. On the other hand, the upstream 
deletion breakpoint at position 117,814,822 contained 
the sequence TGGGGA (Fig. 7), which matches the gen-
eral sequence TGRRKM of the deletion hotspot consen-
sus sequence described in the literature (Krawczak and 
Cooper 1991; Abeysinghe et  al. 2003). Another 10  bp 
upstream, the same hotspot sequence occurred on the 
lower DNA strand. Furthermore, a third copy of the hot-
spot sequence was found at the downstream breakpoint 
on the lower strand. Thus, our case is most consistent 
with the classical mechanism of NHEJ. It is conceivable 
that DNA polymerase paused at the deletion breakpoint 
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Fig. 3 Localization of the mutation. Agarose gels stained with 
ethidium bromide are shown. a PCR amplification of the region 
corresponding to nucleotides 2370-2723 of the exostosin-1 mRNA 
(NM_000127.2) yielded two fragments of 354 and 264 bp, respec-
tively, with samples from the mother #8 and her sons #13 and #14, 
but a single fragment with samples from an unrelated control as well 
as from father #7 and the healthy brother #12. b Long-range PCR of a 
fragment corresponding to the region from intron 7 to intron 8 of the 
EXT1 gene yielded two fragments of 5.6 and 1.4 kb, respectively, with 
samples from mother #8 and son #13, but a single fragment with 
samples from father #7 and the healthy son #12
GGAGAGAGCAAGGTGGATTTCGCC
CCTCTCTCGTTCCACCTAAAGCGG
 G  E  S  K  V  D  F  A
Exon 8Exon 7 Exon 9
GGAGAGAGCAAGGTGGATTTCGCC
CCTCTCTCGTTCCACCTAAAGCGG
 G  E  S  K  V  D  F  A
Exon 8 Exon7Exon 9
CAGATTTGGGGAATAGCAATTCCA
GTCTAAACCCCTTATCGTTAAGGT
CAGATTTGGGGAATAGCAATTCCA
GTCTAAACCCCTTATCGTTAAGGT
a
b
Fig. 4 Sequencing of mutated exostosin-1 from patient #13. a Parts 
of the original sequencing chromatograms of the EXT1 cDNA are 
shown together with the DNA sequence of both strands and the 
deduced amino acid sequence in single letter code. The left panel 
shows sequencing from the 5′ end, the right panel sequencing from 
the 3′ end (complementary strand). Note that the cDNA sequence 
of patient #13 leads from the region of exon 7 directly into the 
region of exon 9. b Parts of the sequencing chromatograms of the 
genomic EXT1 DNA are depicted together with the DNA sequence. 
The position where a deletion is found when compared to the 
EXT1 gene (NC_000008.11) is indicated by an arrow. The left panel 
shows sequencing from the 5′ end of the EXT1 gene, the right panel 
sequencing from the 3′ end
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hotspot sequences during replication (Krawczak and 
Cooper 1991). This replication arrest might have pro-
longed the single-stranded state of the DNA and made 
it vulnerable to illegitimate recombination. Finally, the 
mutated allele was inherited from mother #8 to her sons 
#13 and #14.
Discussion
In this study, we have investigated the molecular cause of 
MO syndrome in a family with three affected members. 
By PCR amplification and DNA sequencing, we were able 
to identify a discrete deletion of 4318  bp that includes 
exon 8 of the EXT1 gene and parts of the flanking introns.
EXT1 mut
EXT1 wt
1 60
1 60
MQAKK RY F I L L S AG S C L A L L F Y F GG L Q F RA S R S H S R R E E H S GRNG L HH P S P DH FWP R F P D
MQAKK RY F I L L S AG S C L A L L F Y F GG L Q F RA S R S H S R R E E H S GRNG L HH P S P DH FWP R F P D
EXT1 mut
EXT1 wt
61 120
61 120
A L R P F V PWDQ L E N E D S S VH I S P RQKRDAN S S I YKGKKC RME S C F D F T L CKKNG F KVYVY P
A L R P F V PWDQ L E N E D S S VH I S P RQKRDAN S S I YKGKKC RME S C F D F T L CKKNG F KVYVY P
EXT1 mut
EXT1 wt
121 180
121 180
QQKG E K I A E S YQN I L AA I E G S R F Y T S D P S QAC L F V L S L D T L DRDQ L S P QYVHN L R S KVQ S
QQKG E K I A E S YQN I L AA I E G S R F Y T S D P S QAC L F V L S L D T L DRDQ L S P QYVHN L R S KVQ S
EXT1 mut
EXT1 wt
181 240
181 240
L H LWNNGRNH L I F N LY S G TWP DY T E DVG F D I GQAML AKA S I S T E N F R P N F DV S I P L F S KD
L H LWNNGRNH L I F N LY S G TWP DY T E DVG F D I GQAML AKA S I S T E N F R P N F DV S I P L F S KD
EXT1 mut
EXT1 wt
241 300
241 300
H P R T GG E RG F L K F N T I P P L RKYMLV F KGK RY L T G I G S D T RNA LYHVHNG E DVV L L T T CKH
H P R T GG E RG F L K F N T I P P L RKYMLV F KGK RY L T G I G S D T RNA LYHVHNG E DVV L L T T CKH
EXT1 mut
EXT1 wt
301 360
301 360
GKDWQKHKD S R CDRDN T E Y E KYDYR EML HN AT F C LV P RGR R L G S F R F L E A L QAACV P VML
GKDWQKHKD S R CDRDN T E Y E KYDYR EML HN AT F C LV P RGR R L G S F R F L E A L QAACV P VML
EXT1 mut
EXT1 wt
361 420
361 420
S NGWE L P F S E V I NWNQA AV I GD E R L L L Q I P S T I R S I HQDK I L A L RQQ T Q F LWE AY F S S V E
S NGWE L P F S E V I NWNQA AV I GD E R L L L Q I P S T I R S I HQDK I L A L RQQ T Q F LWE AY F S S V E
EXT1 mut
EXT1 wt
421 480
421 480
K I V L T T L E I I QDR I F KH I S RN S L I WNKH P GG L F V L P QY S S Y L GD F P YY YAN L G L K P P S K F
K I V L T T L E I I QDR I F KH I S RN S L I WNKH P GG L F V L P QY S S Y L GD F P YY YAN L G L K P P S K F
EXT1 mut
EXT1 wt
481 540
481 540
T AV I H AV T P LV S Q S Q P V L K L L VAAAK S QYCAQ I I V LWNCDK P L P AKH RWP A T AV P VVV I E
T AV I H AV T P LV S Q S Q P V L K L L VAAAK S QYCAQ I I V LWNCDK P L P AKH RWP A T AV P VVV I E
EXT1 mut
EXT1 wt
541 570
541 600
G E S K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - VD F A F T VWQ S F P E R I VGY P A R S H FWD
G E S KVMS S R F L P YDN I I T D AV L S L D E D T V L S T T E VD F A F T VWQ S F P E R I VGY P AR S H FWD
EXT1 mut
EXT1 wt
571 630
601 660
N S K E RWGY T S KWT NDY SMV L T GAA I YHKYYHY LY S HY L P A S L KNMVDQ L ANC E D I LMN F L
N S K E RWGY T S KWT NDY SMV L T GAA I YHKYYHY LY S HY L P A S L KNMVDQ L ANC E D I LMN F L
EXT1 mut
EXT1 wt
631 690
661 720
V S AV T K L P P I KV T QKKQYK E TMMGQ T S RA S RWAD P DH F AQRQ S CMN T F A SWF GYMP L I H S
V S AV T K L P P I KV T QKKQYK E TMMGQ T S RA S RWAD P DH F AQRQ S CMN T F A SWF GYMP L I H S
EXT1 mut
EXT1 wt
617196
647127
QMR L D P V L F KDQV S I L RKKYRD I E R L
QMR L D P V L F KDQV S I L RKKYRD I E R L
Fig. 5 Sequence of mutant exostosin-1 from patient #13. The amino acid sequence derived from the mRNA sequence was compared with the 
published protein sequence of exostosin-1 (NP_000118). The relative locations of introns in the EXT1 gene are indicated by arrows. Note that the 
sequence of patient #13 exactly lacks the region of the protein, which is derived from exon 8. The positions of two polymorphisms (rs7837891 and 
rs11546829) that were found in the cDNA are marked by asterisks. They did not lead to any change in the amino acid sequence
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In contrast to many other studies, which rely on exon 
sequencing of genomic DNA, we have started from puri-
fied RNA of the index patient and analyzed the sequences 
of the EXT1 and EXT2 mRNAs. We reasoned that leu-
kocytes from the patient’s blood must contain heparan 
sulfate proteoglycans on their cell surfaces and conse-
quently contain detectable levels of mRNA for these gly-
cosyltransferases. It is likely that we would have missed 
the relatively short deletion of exon 8 if we had used 
exome sequencing. In fact, a primer pair flanking this 
exon amplified a fragment with the expected size from 
the intact allele, whereas no product was obtained from 
the mutant allele.
Large genomic deletions spanning several kb of 
genomic DNA are usually detected by fluorescent in situ 
hybridization (FISH). However, short deletions spanning 
only a few hundred bp are difficult to identify by this 
method due to its limited sensitivity. In this case, quanti-
tative comparative hybridization to a gene array contain-
ing genomic DNA fragments (array-CGH) is the method 
of choice. But again, short deletions as in our case are 
difficult to detect by gene arrays, especially when these 
arrays are based on common SNPs with poor resolution. 
In order to detect short deletions, some researchers have 
developed special arrays with “tiling resolution” that con-
tained synthetic DNA fragments based on the genomic 
9xE8xE7xE
Deletion of 4318 bp
5473 bp
pb7213pb2163
117,814,822 117,810,504
AluLTR MIR MIR Alu L2 MIRLTRAluLTRAlu
pb161pb0996 bp
8nortnI7nortnI
5494 bp
MIR
Fig. 6 Schematic drawing of the mutated region of the EXT1 gene at chromosomal location 8p24 from patient #13. Exons (Ex7, Ex8, Ex9) are given 
as black boxes, introns as straight lines. Repetitive elements (MIR, LTR, Alu, L2) are depicted as open boxes. The wildtype allele is shown at the top, the 
mutant allele at the bottom. Note that patient #13 contains a deletion of 4318 bp that includes exon 8. The two deletion breakpoints occur close to, 
but not within repetitive elements
Upstream Breakpoint 117,814,824/117,814,822 
AGCTGGCTCCTAGGGGTACTCAGATTTGGGGA / gactgcagctctggcagctggctaggtacctc 
Downstream Breakpoint 117,810,504/117,810,506 
catcctcatgctggtgaatttcttttcaaaga / ATAGCAATTCCAACCACTCAATGCATGCTGGG 
Fig. 7 Deletion breakpoints of the mutant allele from patient #13. The deleted sequence is shown in lower case letters. The upstream breakpoint 
(relative to the orientation of the EXT1 gene) occurs at position 117,814,822 of the EXT1 gene, the downstream breakpoint at position 117,810,504. 
Since the deletion breakpoints contain a microrepeat of 2 nucleotides (GA), the breakpoints are slightly ambiguous. Note that the EXT1 gene is 
located on the lower strand of chromosome 8 at region 8p24. Close to the breakpoints, three copies of the deletion hotspot consensus sequence 
TGRRKM are found (highlighted in red)
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sequence of interest (Szuhai et  al. 2011). However, such 
arrays are not commercially available and have to be pre-
pared individually for each project.
The most common mutations identified in MO patients 
are frameshift mutations (44  %), nonsense mutations 
(24  %), and splice site mutations (11  %). In most cases, 
these mutations result in premature termination of transla-
tion and polypeptide truncation (Jennes et  al. 2009). Fur-
thermore, it is likely that the affected mRNAs are degraded 
by nonsense-mediated decay NMD (Miller and Pearce 
2014). Deletions, especially deletions of a single exon as 
in our case, are rather rare. Jennes et al. (2008) analyzed a 
cohort of 63 MO patients and found only 3 patients with 
EXT1 deletions. Furthermore, we are aware of only one 
additional family with a deletion of exon 8 alone, which has 
been published in the literature (Jennes et al. 2008, 2011). It 
is of interest to note that the exact deletion breakpoints dif-
fer between our family (117,814,822-117,810,504) and the 
one reported in the literature (117,815,648-117,809,763).
Exon 8 is 90  bp long and codes for 30 amino acids. 
Since it is flanked by splice sites of phase 0, deletion will 
not change the reading frame. Thus, the transcribed 
mRNA will contain the normal stop codon and the nor-
mal 3′UTR; consequently it will not be recognized by 
NMD for degradation. In fact, we observed roughly equi-
molar amounts of the cDNAs from the wildtype allele 
and from the mutated allele. It is possible that this fact 
makes the mutation particularly devastating as discussed 
in the following.
The 3D structures of EXT1 and EXT2 are not yet 
known. However, the 3D structure of the homologous 
glycosyltransferase ExtL2 from mouse has been eluci-
dated by X-ray crystallography (Pedersen et  al. 2003). 
Although the primary sequences of the individual mem-
bers of the EXT family show rather a low degree of con-
servation, most of the residues involved in binding of the 
donor sugar (in this case UDP-GlcNAc) and the catalytic 
metal ion (Mn2+) are highly conserved (Fig.  8). It has 
therefore been suggested that the pocket for binding of 
the donor UDP-sugar should exhibit a similar structure 
in all members of the EXT family (Pedersen et al. 2003).
In a pairwise alignment (Fig.  8) the portion of the 
human EXT1 sequence, which is encoded by exon 8 but 
missing in our patients, aligns with residues 131-160 of 
mouse ExtL2. This is exactly the region that would inter-
act with the UDP-sugar and the essential manganese 
ion. The DXD motif, which represents the signature of 
all UDP-sugar dependent glycosyltransferases (Breton 
and Imberty 1999), is found in mouse ExtL2 at residues 
151-153. The two aspartate residues have been shown to 
interact with Mn2+ and the UDP-sugar and to position 
them in the proper orientation for catalysis (Pedersen 
et  al. 2003). This motif is conserved as 565-DED-567 
in human EXT1. Furthermore, residue R135 of mouse 
ExtL2, which forms a hydrogen bond with the donor 
sugar, is conserved as R549 in human EXT1 (Fig.  8). 
Based on this alignment, it is obvious that the EXT1 pro-
tein of our patients must be enzymatically inactive.
Quantitative analysis of the glycosyltransferase activity 
of mutated EXT1 proteins from several MO patients has 
shown that the residual enzyme activity was much lower 
than 50 % as would be expected in the heterozygous state 
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Fig. 8 Alignment of the amino acid sequences of mouse ExtL2 (NP_001156986) and human EXT1 (NP_000118). Homologies are boxed and shaded 
according to identity (dark grey) and similarity (light grey). Although the two EXT proteins do not show much sequence homology, most of the 
critical amino acid residues, which are known to interact with the catalytic manganese ion and the UDP-sugar, are conserved (marked in red). The 
sequence encoded by exon 8 of the human EXT1 gene is given in brackets. It harbors the DXD signature (indicated by three asterisks) present in all 
UDP-dependent glycosyltransferases as well as a critical arginine residue that forms a hydrogen bond with the donor sugar
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(Hecht et al. 2005; Cheung et al. 2001). Theoretically there 
are two ways to explain why mutation of a single EXT1 
copy might result in MO in a dominant fashion. Either, 
the residual glycosyltransferase activity is not sufficient 
to fulfill the function of the enzyme (haploinsufficiency), 
or alternatively, the mutated protein exerts a dominant 
negative effect on the activity of the wildtype protein. 
Work with knockout mice has provided evidence against 
the first possibility. Homozygous Ext1 knockout mice 
(expected Ext enzyme levels 0  %) are lethal and die at 
embryonic day E8.5, indicating the importance of heparan 
sulfate for embryonic development (Lin et al. 2000). How-
ever, heterozygous knockout mice (expected Ext enzyme 
levels 50 %) are largely normal and lack an obvious skel-
etal phenotype, thus ruling out haploinsufficiency in mice 
(Hilton et al. 2005). Likewise, homozygous Ext2 knockout 
mice are embryonically lethal. However, heterozygous 
Ext2 knockout mice develop, although with very low fre-
quency, exostosis-like protrusions along the ribs, suggest-
ing that a partial loss of the Ext glycosyltransferase activity 
may be sufficient for exostosis formation (Stickens et  al. 
2005). Moreover, compound heterozygous mice lacking 
one allele of Ext1 plus one allele of Ext2 frequently exhibit 
exostoses on the long bones (Zak et al. 2011). These mice 
should possess approximately 25 % of the Ext enzyme lev-
els when compared to wildtype littermates. Thus, a sig-
nificant, but not necessarily a complete loss of Ext protein 
expression is sufficient to explain exostoses formation.
Our MO patients contain a heterozygous deletion in 
EXT1 and show only a relatively small reduction of the 
normal EXT1 mRNA levels (Fig. 3a). Mutation of the sec-
ond allele (loss of heterozygosity) in somatic cells would 
explain a further decrease of EXT enzyme activity, but 
loss of heterozygosity is very rare and has been ruled out 
in the majority of the MO patients (Hall et al. 2002). It is 
therefore likely that the mutant protein encoded by the 
affected allele exerts a dominant negative effect on the 
intact protein encoded by the wildtype allele.
How can we explain a dominant negative effect of the 
mutated EXT1 protein? EXT1 is known to form an oli-
gomeric complex with EXT2 (Kobayashi et  al. 2000; 
McCormick et al. 2000; Senay et al. 2000). It is likely that 
this complex contains several copies of EXT1 and EXT2 
(e.g. stoichiometry 2:2 or 4:4) because it has to interact 
with the nascent chain of heparan sulfate that consists of 
at least four sugar residues, the starting tetrasaccharide 
(Nadanaka and Kitagawa 2008). It is therefore conceivable 
that incorporation of a mutated copy of EXT1 into such 
an assembly will render the entire complex inactive. One 
false copy could therefore compromise the activity of sev-
eral normal copies of the polypeptide. Since the N-termi-
nal domain of EXT1, which is involved in protein–protein 
interactions, remains intact in our case, it is likely that the 
mutated enzyme will still be incorporated into the final 
complex. Faithful incorporation of a mutant protein into 
an oligomeric complex would thus explain a dominant 
negative effect. However, it should be emphasized that 
there might be additional ways to explain a dominant neg-
ative effect.
Conclusion
We have demonstrated that sequencing of the mRNA, 
rather than the genomic DNA, might offer an advantage 
over exome sequencing if one is searching for short dele-
tions spanning only a few hundred bp. It remains to be 
determined whether deletions affecting a single exon are 
more common than initially thought because they were 
missed by exome sequencing in some reports.
Methods
RNA isolation
Total RNA was isolated from the blood of the patients 
using the QIAamp RNA Blood Mini kit from Qiagen 
(Hilden, Germany). Written consent was obtained to use 
the samples for genetic testing and to publish the results 
in accordance with the guidelines of the Swiss Society of 
Medical Genetics (www.sgmg.ch).
The blood (2  ml) was collected in the presence of 
the anti-coagulant EDTA and immediately processed. 
Erythrocytes were lysed in hypotonic buffer. Leuko-
cytes were collected by centrifugation, lysed with a 
QIAshredder and dissolved in RLT buffer. Total RNA 
was adsorbed to a silica-based membrane, washed and 
selectively eluted with TE buffer. The purified RNA 
was transcribed into first-strand cDNA using hexamer 
primers and Improm-II Reverse Transcriptase (Pro-
mega, Madison WI, USA).
Isolation of genomic DNA
DNA was isolated from freshly drawn blood using the 
Wizard genomic DNA purification kit from Promega. 
Red blood cells were lysed in Cell Lysis Solution. White 
blood cells were collected by centrifugation and lysed 
in Nuclei Lysis Solution. RNA was digested with RNase 
and cellular proteins were removed by salt precipitation. 
Finally, the genomic DNA was concentrated by precipita-
tion with isopropanol and washed with ethanol.
PCR amplification and DNA sequencing
Fragments of interest were amplified from the cDNA by PCR 
through 35 cycles (20″ at 95 °C, 20″ at individual annealing 
temperature (Additional file 1: Table S1), 15″ at 72 °C) with 
KAPA high fidelity DNA polymerase (KAPA Biosystems, 
Boston, USA). The fragments were resolved on 1 % agarose 
gels. Single bands were recovered from the agarose gel with 
the GeneElute extraction kit (Sigma, St. Louis MO, USA). 
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For long-range PCR, the cycle number was reduced to 33 
and the extension time at 72 °C was increased to 2′ 40″. In 
this case, the amplified fragments were resolved on a 0.5 % 
agarose gel. DNA sequences were determined by Sanger 
cycle sequencing on an ABI 3730 platform.
Sequence analysis
All sequences were analysed with the program package 
of MacVector Inc. For sequence alignments, the program 
ClustalW was used with the following parameters: Scor-
ing matrix Gonnet, open gap penalty 10, extend gap pen-
alty 0.1. Transmembrane sequences and PFAM protein 
domains were identified with the simple modular archi-
tecture research tool (Schultz et al. 1998).
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